NCT05653986View on ClinicalTrials.gov

An Observational Study to Assess Change in Disease Activity When Ubrogepant Tablets Are Combined With Atogepant Tablets to Treat Migraine in Adult Participants

CompletedOBSERVATIONAL
Enrollment

391

Participants

Timeline

Start Date

December 18, 2022

Primary Completion Date

August 5, 2024

Study Completion Date

August 5, 2024

Conditions
Migraine
Trial Locations (1)

10461

Montefiore/Albert Einstein /ID# 252243, The Bronx

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY

NCT05653986 - An Observational Study to Assess Change in Disease Activity When Ubrogepant Tablets Are Combined With Atogepant Tablets to Treat Migraine in Adult Participants | Biotech Hunter | Biotech Hunter